AK112 for limited-stage small cell lung cancer after chemoradiation
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new drug called AK112 (a bispecific antibody that blocks both PD-1 and VEGF) as a consolidation treatment to help prevent your limited-stage small cell lung cancer from coming back after you've finished chemoradiation. It's for people whose cancer has not grown following concurrent chemotherapy and radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have limited-stage small cell lung cancer (stage I–III, not spread beyond one lung and nearby lymph nodes).
- You have completed concurrent chemotherapy and radiation (chemoradiation) and your cancer has not grown afterward.
- You have not had any prior treatment that targets the immune system (like checkpoint inhibitors, immune cell therapy) or that blocks blood vessel growth (anti-angiogenic therapy).
- You do not have an active autoimmune disease or a history of interstitial lung disease (lung scarring or inflammation).
- You are generally active enough to care for yourself (ECOG status 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called AK112 combined with chemotherapy (nab-paclitaxel) for people with advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if AK112 works better than a placebo at shrinking tumors and helping people live longer.
This trial is for people with limited-stage small cell lung cancer who have finished chemoradiation and still have small amounts of cancer DNA in their blood (called MRD-positive). The study tests a new treatment strategy after chemoradiation, and it may help reduce the chance of the cancer coming back.
This trial tests a new immunotherapy drug called AK112 for people with advanced liver cancer that hasn't spread to the brain or key blood vessels. It may be an option if you haven't had immunotherapy before and your liver is still working well.
This trial tests a new drug, AK112, combined with chemotherapy for people with advanced non-squamous non-small cell lung cancer that has spread to the lining of the lung (malignant pleural effusion). The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial tests a new drug called AK112 for people with a certain type of advanced lung cancer that has specific gene changes (like EGFR or ALK) and where previous targeted therapy pills stopped working. It is a phase 2 study, so it helps find out if the drug is safe and effective, possibly offering a new option when standard treatments fail.
This trial tests a combination of two experimental drugs, AK146D1 and AK112, for people with advanced non-small cell lung cancer that cannot be removed by surgery or treated with standard chemo-radiation. It aims to find out if this combination can shrink tumors or slow cancer growth.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.